Loading...
•
Jan 23
Medtronic Q3 2026 Earnings Report
Medtronic reported strong third quarter fiscal 2026 results with the highest enterprise revenue growth in 10 quarters, driven by Cardiovascular and Diabetes momentum.
Key Takeaways
Medtronic generated third quarter fiscal 2026 revenue of 9017000000, up 8.7% reported and 6.0% organic, with GAAP net income of 1143000000 and diluted EPS of 0.89. Growth was led by double-digit Cardiovascular performance and strong Diabetes expansion, while operating margins remained solid.
Revenue increased to 9017000000, up 8.7% reported and 6.0% organic.
GAAP net income was 1143000000 with diluted EPS of 0.89.
Cardiovascular revenue rose 13.8% to 3457000000.
Non-GAAP operating margin reached 24.1%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company reiterated fiscal 2026 guidance, expecting approximately 5.5% organic revenue growth and non-GAAP diluted EPS between 5.62 and 5.66, including an estimated tariff impact of 185000000.
Positive Outlook
- FY26 organic revenue growth expected at approximately 5.5%.
- Non-GAAP diluted EPS guidance between 5.62 and 5.66.
- Excluding tariffs, EPS growth projected at approximately 4.5%.
- Strong innovation pipeline supporting sustained growth.
- Portfolio breadth driving diversified expansion.
Challenges Ahead
- Potential tariff impact of approximately 185000000.
- Exposure to foreign currency fluctuations.
- Ongoing regulatory compliance costs.
- Restructuring and acquisition-related expenses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...